The Chemical Entities of Biological Interest (ChEBI) ontology is downloaded weekly from EMBL-EBI at http://www.ebi.ac.uk/chebi/. The data is made available under the Creative Commons License (CC BY 3.0, http://creativecommons.org/licenses/by/3.0/). For more information see: Degtyarenko et al. (2008) ChEBI: a database and ontology for chemical entities of biological interest. Nucleic Acids Res. 36, D344–D350.
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate] APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate Triazines inhibits the reaction [IDH2 protein mutant form results in increased abundance of fructose-1,6-diphosphate]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [APP protein mutant form results in decreased abundance of fructose-1,6-diphosphate] [APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased chemical synthesis of sodium arsenite; [GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog; heptelidic acid inhibits the reaction [[GAPDH protein co-treated with fructose-1,6-diphosphate co-treated with NAD] results in increased reduction of sodium arsenate analog]
IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate; PF-06840003 inhibits the reaction [[amyloid beta-protein (1-42) binds to MAPT protein] which results in decreased abundance of fructose-1,6-diphosphate] MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate PF-06840003 inhibits the reaction [MAPT protein mutant form results in decreased abundance of fructose-1,6-diphosphate]
fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 mRNA]; fructose-1,6-diphosphate inhibits the reaction [Lipopolysaccharides results in increased expression of NOS2 protein] fructose-1,6-diphosphate results in decreased degradation of NOS2 mRNA
[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate; IDO1 protein affects the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]; PF-06840003 inhibits the reaction [[APP protein mutant form co-treated with PSEN1 protein mutant form] results in decreased abundance of fructose-1,6-diphosphate]
browse the term
